公开(公告)号：US20180125875A1

公开(公告)日：2018-05-10

申请号：US15126777

申请日：2015-03-17

Applicant: Hiroshi Ide ,  STC.UNM

Inventor： Yoshihiro Matsumoto ,  Alan Edward Tomkinson ,  Hiroshi Ide

IPC: A61K31/7072 ,  A61K31/513 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/7072 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/519 ,  A61K31/55 ,  A61K31/555 ,  A61K31/675 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/14 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/00

Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2′-deoxyuridine (fdU or foUdR) or a 5-formyl-2′-deoxyuridine derivative, optionally in combination with 5-hydroxy-2′-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5-fluoro-2′-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2′-deoxyuridine (FdU). Related pharmaceutical compositions are also provided.

公开(公告)号：US10086010B2

公开(公告)日：2018-10-02

申请号：US15126777

申请日：2015-03-17

Applicant: STC.UNM ,  Hiroshi Ide

Inventor： Yoshihiro Matsumoto ,  Alan Edward Tomkinson ,  Hiroshi Ide

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/7072 ,  A61K31/513 ,  A61P35/00 ,  A61K45/06 ,  A61K31/7064 ,  A61K31/706 ,  A61K31/7068

Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2′-deoxyuridine (fdU or foUdR) or a 5-formyl-2′-deoxyuridine derivative, optionally in combination with 5-hydroxy-2′-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5-fluoro-2′-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2′-deoxyuridine (FdU). Related pharmaceutical compositions are also provided.